Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis

Background Programmed death ligand 1 (PD‐L1) inhibitor has been approved as one of the standard therapies for various cancers. Some reports have shown that serum PD‐L1 level is associated with advanced tumor stages and poor prognosis; however, corresponding pathological information in esophageal cancer patients is lacking. Therefore, we evaluated the clinicopathological and prognostic impact of serum PD‐L1 levels in surgically treated esophageal cancer. Methods A total of 150 patients who underwent radical resection for esophageal cancer were included in the study. Preoperative serum PD‐L1 levels were analyzed using the enzyme‐linked immunosorbent assay kit. A cutoff level of 65.6 pg/mL was used to divide the patients into two groups, and univariate and multivariate analyses were conducted to compare the clinicopathological characteristics and prognoses between these two groups. Results Although significant associations between serum PD‐L1 levels and clinicopathological variables were observed, serum PD‐L1 level was significantly associated with high neutrophil counts, high CRP levels, low albumin levels, and high squamous cell carcinoma antigen levels. Furthermore, serum PD‐L1 level was associated with poor overall survival independent to TNM factors. Conclusions High preoperative level of serum PD‐L1 is a prognostic factor for poor overall survival in patients with surgically treated esophageal cancer.

show abstract

“…The cut off level of NLR and PLR was set as follows NLR; 1.6, PLR; 117.07 according to previous reports. 16,17…”

Section: Serum Sampling and Enzyme Immunoassay For Serum Markersmentioning

confidence: 99%

High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Numerous prognostic factors, including TNM stage, have been reported . However, recently, inflammatory and nutritional markers such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and C‐reactive protein to albumin ratio (CAR) have been recognized as useful prognostic markers for esophageal cancer patients worldwide . Of note, the majority of these investigations were retrospective cohort studies.…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of systemic inflammatory markers in esophageal cancer: Systematic review and meta‐analysis

Ishibashi

Tsujimoto

Yaguchi

et al. 2019

Annals of Gastroent Surgery

View full text Add to dashboard Cite

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractAim: Impact of several immune-inflammatory markers on long-term outcome has been reported in various malignancies. The aim of the present study was to evaluate through a meta-analysis the oncological outcome of immune-inflammatory markers, such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and C-reactive protein to albumin ratio (CAR) in esophageal cancer. Methods: A systematic electronic search for relevant studies was carried out inPubMed, Cochrane library, Embase, and Google scholar. Meta-analysis was done using hazard ratio (HR) and 95% confidence interval (CI) as effect measures. A systematic review and meta-analysis were undertaken according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol. P-values <.01 were considered statistically significant.Results: A total of 10 retrospective articles (n = 4551) were included in this study.Synthesized results showed that higher NLR and CAR were significantly associated with poor overall survival (HR 1.47, 95% CI = 1.32-1.63, P < .00001) and HR 1.88, 95% CI = 1.28-2.77, P < .001, respectively). On the contrary, PLR was not a prognostic factor in our analysis (HR 1.25, 95% CI = 1.01-1.54, P < .01). Elevated NLR, PLR, and CAR were strongly associated with a higher T stage (HR 2.28, 95% CI = 1.67-3.11; HR 1.57, 95% CI = 1.29-1.90; HR 1.76, 95% CI = 1.16-2.67, respectively). Begg's funnel plots identified significant publication bias in NLR, but not in PLR and CAR.Conclusion: NLR and CAR represent useful guides for the management of esophageal cancer, although publication bias should be considered. Further prospective studies are needed to confirm the results of the present study.

show abstract

“…The SII should be a more objective marker that reflects the balance between host inflammatory and immune responses than all the other systemic inflammation scores. Geng et al showed SII to be superior to the above indices as a prognostic predictive factor in patients with esophageal squamous cell carcinoma (8). A previous study showed that non-steroidal anti-inflammatory drugs have a role in the prevention and treatment of cancer (23) Therefore, there is a possibility that pw NSCLC who have a high SII may especially benefit from targeted anti-inflammatory with aspirin and non-steroidal anti-inflammatory drugs.…”

Section: Discussionmentioning

confidence: 99%

“…Geng et al suggested that SII was superior to other such indices, such as NLR, and served as a more objective marker that reflects the balance between host inflammatory and immune response status in patients with esophageal squamous cell carcinoma (8).…”

mentioning

confidence: 99%

Systemic Immune-inflammation Index Predicts Survival of Patients After Curative Resection for Non-small Cell Lung Cancer

2018

View full text Add to dashboard Cite

Abstract. Background: The systemic immune-inflammation index (SII) is reported to be associated with clinical outcomes and has been proven to be a promising prognostic indicator inCancer-related inflammation is an essential component of the tumor microenvironment, and inflammatory cells may play a critical role in tumor development and progression (1). It has been shown that markers of inflammation and scoring systems based on the systemic inflammatory response are of prognostic value in patients with non-small cell lung cancer (NSCLC) (2). In particular, various combinations of hematological parameters [including C-reactive protein (CRP) concentration, the neutrophil-to-lymphocyte ratio (NLR), and the Glasgow prognostic score (GPS)] have been evaluated as predictors of recurrence or survival in NSCLC (3-6).Recently, a novel index named the systemic immuneinflammation index (SII), based on the peripheral lymphocyte, neutrophil and platelet counts, was investigated as a prognostic marker in several tumor types (7). Geng et al. suggested that SII was superior to other such indices, such as NLR, and served as a more objective marker that reflects the balance between host inflammatory and immune response status in patients with esophageal squamous cell carcinoma (8).With regard to lung cancer, the prognostic significance of SII was reported for small cell lung cancer (9) and stage III NSCLC (10). However, to our knowledge, there are no previous studies that evaluated the significance of SII for resectable NSCLC. Therefore, in the present study, we examined the prognostic significance of SII in patients with resectable NSCLC. Patients and MethodsThis retrospective study was approved by our Institutional Review Board (O-0255) and the need to obtain patient consent was waived. We retrospectively reviewed data from 341 patients (with 173 men and 168 women, median age of 69 years) who underwent complete resection for NSCLC at our hospital from January 2008 to December 2012. The inclusion criteria were as follows: histologically confirmed NSCLC and complete clinical, laboratory, imaging and follow-up data. The exclusion criteria included: preoperative chemotherapy/radiotherapy or death during the 663

show abstract

Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis

Cited by 207 publications

References 28 publications

High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer

High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer

Prognostic significance of systemic inflammatory markers in esophageal cancer: Systematic review and meta‐analysis

Systemic Immune-inflammation Index Predicts Survival of Patients After Curative Resection for Non-small Cell Lung Cancer

Contact Info

Product

Resources

About